<DOC>
	<DOCNO>NCT00844506</DOCNO>
	<brief_summary>The purpose study determine whether addition cyclophosphamide treatment p53-SLP vaccine improve clinical efficacy immunogenicity p53-SLP vaccine ovarian cancer patient .</brief_summary>
	<brief_title>p53 Synthetic Long Peptides Vaccine With Cyclophosphamide Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Written inform consent . Histological proven epithelial ovarian carcinoma . At least 4 week termination last course chemotherapy . Rising CA125 serum level `` first line '' treatment measurable disease accord RECIST ( Response Evaluation Criteria Solid Tumours ) criterion , Rising CA125 serum level `` first line '' treatment measurable disease accord RECIST ( Response Evaluation Criteria Solid Tumours ) criterion , willing otherwise fit receive `` second line '' chemotherapy . Age 18 year old , life expectancy least 3 month . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial . Performance status 0 2 ( WHO scale ) . Adequate hepatic , renal , bone marrow function define : ASAT &lt; 100 U/l ; ALAT &lt; 113 U/l ; PT 912 second ; APTT 2333 second ; creatinine &lt; 135 Î¼mol/l ; WBC &gt; 3.0 x 109/L ; platelet &gt; 100 x 109/L ; hemoglobin &gt; 6.0 mmol/l . Adequate venous access blood collection i.v . administration cyclophosphamide . Pregnancy / breast feeding . ( A ) symptomatic cystitis . Other malignancy ( previous current ) , except basal squamous cell carcinoma skin . Immunosuppressive agent , except topical inhalation corticosteroid . Prior therapy biological response modifier . Any major disease may interfere conduct study ( e.g . uncontrolled hypertension , severe and/or unstable heart disease , neurological psychiatric disorder ) . Signs symptom CNS metastasis . Known substance abuse ( drug alcohol ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Ovarian cancer patient recurrent disease</keyword>
</DOC>